The FDA has granted fast track status to 67Cu-SAR-bisPSMA for metastatic prostate cancer that is resistant to hormone therapy ...

Investigators report that estradiol works as well as luteinizing hormone–releasing hormone agonists for testosterone suppression and have a much better side-effect profile.

A major discovery by Australian researchers of a key driver of prostate cancer could lead to the next generation of targeted ...

“Prostate-specific membrane antigen (PSMA) PET imaging can identify patients suitable for PSMA-targeted radioligand therapy such as lutetium-177-PSMA-617. This is crucial for mCRPC patients who have ...

11, 2025 — Researchers have discovered a new mechanism that is used by a male sex hormone ... Radiation Therapy Reduces Long-Term Side Effects for Patients With Prostate Cancer Nov. 13, 2024 ...

A recent study published in the Journal of Cancer Research and Clinical Oncology explored genetic predictors of prostate cancer progression to help identify its clinical outcomes.

Transdermal estradiol patches may be an alternative to LHRHas when combined with ARPIs to treat mHSPC, researchers say.

Real-world data suggest that, although guideline-concordant care is on the rise, many US patients with mHSPC may not receive it.

Melbourne-based scientists have, for the first time, discovered how to "switch off" a molecule which is one of the top ...

Senior doctors responsible for monitoring cancer care in England and Wales are concerned failings in NHS services are ...